Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy

Immune biomarkers in circulating cells of NSCLC patients can effectively evaluate the efficacy of chemotherapy combined with anti-PD-1 therapy

IntroductionThe application of programmed cell death protein 1 (PD-1) antibodies has brought significant benefits to patients with non-small cell lung cancer (NSCLC). However, not all patients respond to PD-1 immune therapy. The aim of this study was to identify response biomarkers to predict the ef...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Cao, Yuehua Zhang, Shenghu Guo, Zheng Wu, Xiaojin Guo, Rongze Zhang, Lei Zhang, Ya Liu, Xing Li, Chunwang Yang, Dongwei He, Lu Bai, Tingting Lv, Yong Xie, Chengjing Huang, Shuang Xiao, Anyi Deng, Jiawei Li, Jiaxing Zhu, Zhenghu Jia, Zhinan Yin, Zhiyu Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
immune biomarkers
NSCLC
anti-PD-1 therapy
TIM-3
cytokines
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521708/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1521708/full

Similar Items